Low expression of IL-18 and IL-18 receptor in human skeletal muscle is associated with systemic and intramuscular lipid metabolism

Role of HIV lipodystrophy

Lindegaard, Birgitte; Hvid, Thine; Wolsk Mygind, Helene; Mortensen, Ole Hartvig; Grøndal, Thomas; Abildgaard, Julie; Gerstoft, Jan; Pedersen, Bente Klarlund; Baranowski, Marcin

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0186755

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Lindegaard, B., Hvid, T., Wolsk Mygind, H., Mortensen, O. H., Grøndal, T., Abildgaard, J., Gerstoft, J., Pedersen, B. K., & Baranowski, M. (2018). Low expression of IL-18 and IL-18 receptor in human skeletal muscle is associated with systemic and intramuscular lipid metabolism: Role of HIV lipodystrophy. PLoS ONE, 13(1), e0186755. https://doi.org/10.1371/journal.pone.0186755
Low expression of IL-18 and IL-18 receptor in human skeletal muscle is associated with systemic and intramuscular lipid metabolism—Role of HIV lipodystrophy

Birgitte Lindegaard1,2,3*, Thine Hvid1, Helene Wolsk Mygind1, Ole Hartvig-Mortensen4, Thomas Grøndal1, Julie Abildgaard1, Jan Gerstoft2, Bente Klarlund Pedersen1, Marcin Baranowski5

1 The Centre of Inflammation and Metabolism and The Centre of Physical Activity Research, Rigshospitalet, Copenhagen, Denmark, 2 The Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark, 3 The Department of Lung- and Infectious Diseases, Nordsjællands Hospital, Hillerød, Denmark, 4 Department of Biomedical Science, University of Copenhagen, Denmark, 5 Department of Physiology, Medical University of Bialystok, Bialystok, Poland

* birgitte.lindegaard.madsen@regionh.dk

Abstract

Introduction

Interleukin (IL)-18 is involved in regulation of lipid and glucose metabolism. Mice lacking whole-body IL-18 signalling are prone to develop weight gain and insulin resistance, a phenotype which is associated with impaired fat oxidation and ectopic skeletal muscle lipid deposition. IL-18 mRNA is expressed in human skeletal muscle but a role for IL-18 in muscle has not been identified. Patients with HIV-infection and lipodystrophy (LD) are characterized by lipid and glucose disturbances and increased levels of circulating IL-18. We hypothesized that skeletal muscle IL-18 and IL-18 receptor (R) expression would be altered in patients with HIV-lipodystrophy.

Design and methods

Twenty-three HIV-infected patients with LD and 15 age-matched healthy controls were included in a cross-sectional study. Biopsies from the vastus lateralis muscle were obtained and IL-18 and IL-18R mRNA expression were measured by real-time PCR and sphingolipids (ceramides, sphingosine, sphingosine-1-Phosphate, sphinganine) were measured by HPLC. Insulin resistance was assessed by HOMA and the insulin response during an OGTT.

Results

Patients with HIV-LD had a 60% and 54% lower level of muscular IL-18 and IL-18R mRNA expression, respectively, compared to age-matched healthy controls. Patients with HIV-LD had a trend towards increased levels of ceramide (18.3±4.7 versus 14.8±3.0, p = 0.06) and sphingosine (0.41±0.13 versus 0.32±0.07, and lower level of sphinganine (p = 0.06). Low
levels of muscle IL-18 mRNA correlated to high levels of ceramides ($r = -0.31$, $p = 0.038$) and sphingosine-1P ($r = -0.29$, $p = 0.046$) in skeletal muscle, whereas such a correlation was not found in healthy controls. Low expression of IL-18 mRNA in skeletal muscle correlated to elevated concentration of circulating triglycerides ($R_p = -0.73$, $p < 0.0001$). Neither muscle expression of IL-18 mRNA or ceramide correlated to parameters of insulin resistance.

**Conclusion**

IL-18 (mRNA) in skeletal muscle appears to be involved in the regulation of intramuscular lipid metabolism and hypertriglyceridemia.

**Introduction**

The cytokine interleukin (IL)-18 is a member of the IL-1 family and has been identified as a cofactor that, together with IL-12, stimulates production of interferon gamma [1]. IL-18 is widely expressed in many mammalian cells/tissues including liver, adipose tissue and skeletal muscle [2–4] [5]. IL-18 is best known for its role in inflammation, whereby pro-inflammatory stimuli such as lipopolysaccharide, and tumor necrosis factor (TNF)-α leads to caspase-1 mediated cleavage of pro-IL-18 into mature IL-18. IL-18 is synthesized as an inactive precursor molecule (Pro-IL-18) that lacks a signal peptide and requires cleavage into a mature, active cytokine IL-18 that is then secreted from the cell [6].

IL-18 can then signal via a heterodimer of the transmembrane IL-18 receptors (α and β), and via a toll like receptor signaling cascade ultimately leading to the activation of nuclear factor κB (NFκB) and subsequent regulation of gene transcription [7]. Additional signaling pathways of IL-18 also exist, including activation of phosphatidylinositol-3 kinase (PI3K)/Akt [8,9], signal transducer and activator of transcription 3 (STAT 3) [10], mitogen-activated protein kinases (MAPK) [8,10], and c-Jun NH₂-terminal kinase (JNK) [9,11] which are all implicated in energy metabolism.

As IL-18 plays a role in inflammation it is not surprisingly that circulating IL-18 levels are elevated in human obesity [12] and in patients with type 2 diabetes [13,14]. IL-18 is expressed in adipose tissue [15,16] especially in visceral adipose tissue [17,18].

Paradoxically, IL-18 has also been found to be directly involved in the regulation of lipid and glucose metabolism as mice lacking whole-body IL-18 signalling become obese and insulin resistant, [19,20]. In a previous study, we demonstrated that IL-18 receptor deficient mice display obesity, insulin resistance, impaired fat oxidation and ectopic lipid deposition in liver and skeletal muscle [21]. Moreover, administration of IL-18 to whole muscle strips ex vivo increased AMPK signaling and increases fat oxidation, and in vivo electroporation of IL-18 into skeletal muscle results in increased AMPK signaling and expression of mitochondrial genes in skeletal muscle and concomitantly inhibits high fat diet-induced-weight gain, suggesting that IL-18 is increasing skeletal muscle fat oxidation via AMPK and oppose ectopic lipid accumulation [21]. Taken together, in the progression toward obesity, there is continual production of IL-18 to oppose ectopic lipid accumulation [22]. However, the cellular origin of IL-18 remains enigmatic, although it has been shown that IL-18 released from adipose tissue is not produced by the adipocytes themselves [16,23]. Given that IL-18 is expressed in human skeletal muscle and exerts its effect on lipid metabolism in skeletal muscle ex vivo and in vivo
in rodents, it suggests that IL-18 is regulated in skeletal muscle and associated to lipid metabolism. However, the role of IL-18 in skeletal muscle in humans has never been investigated.

A syndrome of lipodystrophy, characterised by subcutaneous fat loss, and a relative increase in central fat accumulation, was previously seen in patients with HIV, when treated with a combination of antiretroviral therapy, including thymidine-nucleoside analogues [24–26]. Lipodystrophy is mostly caused by antiretroviral induced adipose tissue dysfunction [27,28] and is associated with impaired fat oxidation [29,30], ectopic lipid deposition in muscle and liver [24,30–32], and mitochondrial dysfunction in skeletal muscle [33] leading to dyslipidemia and insulin resistance [24,25]. Elevated circulating levels of IL-18 are observed in HIV-infected patients and especially those with lipodystrophy [34,35]. The increase in circulating IL-18 is associated to the fat redistribution and in part derived from subcutaneous adipose tissue [36,37].

The ectopic accumulation of lipids in the skeletal muscle is closely linked with insulin resistance [38]. In the recent years it is found that it is not the total amount of lipid but the lipid intermediates causing insulin resistance. The lipid intermediates account for sphingolipids, e.g. ceramides, sphingosine, sphingoamine, sphingosine-1-P, and diacylglycerol (DAG) [39]. Especially, ceramides [40] and DAG have been supposed to induce insulin resistance [38]. Besides antagonize insulin signalling recent data also shows that ceramides impair mitochondrial functions [41].

In this study, we included material from a cohort of HIV patients with lipodystrophy [42] in order to obtain more information about the metabolic role of IL-18 in humans. Patients with HIV-lipodystrophy share some of the same metabolic disturbances as mice lacking IL-18 signalling but paradoxically the systemic levels of IL-18 are increased in those patients. We therefore aimed at determining whether muscle IL-18 mRNA and IL-18 receptor mRNA are altered, either increased or decreased, in these patients. Given the strong link between ceramides and insulin resistance [38] and mitochondrial function [41], we further studied the possible association of muscle IL-18 mRNA with ceramides and other sphingolipids.

Patients and methods

Patients and controls

A group of 23 HIV-infected men were recruited from the outpatient clinic of the Department of Infectious Disease, Rigshospitalet in Copenhagen. These subjects have been included in a former study and the inclusions of the subjects are described therein [42]. In short, LD was defined clinically by physical examination of peripheral lipoatrophy (defined by the presence of peripheral lipoatrophy with at least one moderate sign of fat loss in face, arms, buttocks, or legs based on a physical examination by a single investigator (BL) using a validated questionnaire developed by Carr et al [43]). All patients were on a stable and effective nucleoside analogue based antiretroviral therapy with no changes during the preceding 8 weeks.

Two groups of healthy controls were included: Fifteen age-matched HIV-negative healthy men served as controls for RT-PCR data (Group 1). These subjects have also been included in the before mentioned study [42]. But as muscle tissue for measurement of sphingolipids from healthy controls in group 1 were available for only two healthy subjects, 17 new healthy age-matched control subjects were included (Group 2). Demographic data were collected for each patient: age, duration of HIV infection, duration and types of all antiretroviral therapy, weight, height, CD4 count, HIV-RNA copies. Inclusion criteria: no signs of ongoing infections; fasting glucose < 7 mmol/L and 120 min glucose after an OGTT < 11.1 mmol/L, no dyslipidemia (triglycerides >1.7 mmol/L and/or HDL-cholesterol <0.9 mmol/L); suppressed viral load (<20 copies/mL). Exclusion criteria: Severe cardiovascular diseases; arthritis; severe neuropathy;
hepatitis C; opportunistic infections that required hospitalisation within the last 6 weeks; dia-
abetes (fasting glucose ≥7 mmol/L or 2-hrs. glucose >11 mmol/L after an OGTT); concurrent
therapy with antidiabetic agents, anticoagulant or any hormones.

Written informed consent was obtained from all subjects according to the requirements
from the local ethical committee and the Helsinki Declaration II, and the approval from the
local ethical committee (KF 01269485: The Ethics Committee of Copenhagen and Frederiks-
berg) was obtained.

Biochemical measurements
Peripheral blood samples were obtained at 8 AM after an overnight fasting. Measurements of
total cholesterol (mmol/L), HDL-cholesterol (mmol/L), LDL-cholesterol (mmol/L), triglycer-
ides (mmol/L), plasma glucose (mmol/L) and insulin (pmol/L), were determined immediately
using routine methods.

CD4 cell counts were calculated by flowcytometry and HIV-RNA copies were measured by
the Amplicor HIV Monitor (Roche Molecular Systems, Branchburg, NJ) (lower limit of dec-
tection: 20 copies/ml).

Body composition analysis
Fat and fat-free tissue masses for whole body, trunk and extremities were measured using
dual-energy X-ray absorptiometry (DXA) scanner (Lunar Prodigy, GE Medical Systems Wis-
consin, USA, version 8.8) [43]. Whole-body and regional fat measurements (trunk and
extremities) were determined as previously described [44].

Maximal oxygen consumption (VO\textsubscript{2max})
An incremental exercise to volitional fatigue was performed between 0800 h and 1000 h on a
cycle ergometer (Monark 839E, Monark Ltd, Varberg, Sweden). Maximal oxygen consump-
tion (VO\textsubscript{2max}) was measured with an indirect calorimetric system (Moxus modular VO2 sys-
tem, AEI Technologies, Pittsburgh, PA) using a 2-way non-rebreathing valve (Hans Rudolph,
Inc. Kansas City, Missouri) which recorded data every 15 seconds. Based on the pre-VO\textsubscript{2max}
test a protocol was designed in order to reach VO\textsubscript{2max} within 8–12 min of exercise start [45].
Exhaustion was defined by two of the following: respiratory exchange ratios >1.10, VO\textsubscript{2} reached a plateau and/or rpm <60 in more than 10 sec.

Insulin sensitivity
Insulin resistance was assessed from several measurements: fasting plasma insulin, homeosta-
sis model (HOMA-IR) [46] and area under the curve (AUC) for the insulin concentration dur-
ing a 75-g oral glucose tolerance test (OGTT)

Muscle tissue biopsies
Muscle tissue biopsies were obtained after an overnight fast by use of the percutaneous biopsy
technique with suction from the quadriceps muscle under local anaesthesia with 2% lidocaine.
Muscle tissue was immediately frozen in liquid nitrogen and stored at –80˚C until analysed.

RNA extraction. RNA was extracted using Trizol™ (Life Technologies) according to man-
ufacturer’s protocol. In short, 1 ml of Trizol™ was added to 20–30 mg of muscle tissue and
homogenized using a Polytron (PT-MR2100, Kinematica) on setting 25–30 for 20–30 s and
placed on ice. All samples were added 100 µl of chloroform, shaken vigorously and incubated
for 5 min on ice. Samples were spun at 12000 g for 15 min at 4˚C, and the upper aqueous
phase was placed in a fresh eppendorph tube. The same volume of isopropanol was added and samples were placed at -20°C for 1 hour followed by centrifugation at 12000 g for 15 min at 4°C. The resulting RNA pellet was washed with 75% ethanol in DEPC-treated water and spun at 6000 g for 10 min at 4°C. The pellets were dissolved in DEPC-treated water.

**Reverse transcription.** One μg of total RNA was reverse transcribed in a 50-μl reaction according to manufacturer’s protocol (Applied Biosystems, Taqman™ reverse transcription reagents) with the use of random hexamer primers. The reactions were run in a Perkin Elmer GeneAmp PCR system 9700 with conditions at 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min.

**Analysis of gene expression levels in muscle tissue.** Samples were analyzed for IL-18 and IL-18 receptor mRNA levels by real-time PCR using an ABI PRISM 7900 sequence detector (PE Biosystems). The gene expression levels were normalized to the housekeeping gene GAPDH (obtained from Applied Biosystems). Human IL-18 (Hs00155517_m1) and human IL-18 receptor (Hs00187256_m1) primers and Taqman® probe were obtained from Applied Biosystems. All reactions were run in triplicates.

Data were quantitated and normalized using the standard curve method.

**Sphingolipid analysis.** The content of S1P, SA1P, sphingosine, sphinganine, and ceramide was determined as described previously in detail (Knapp et al. 2013). Briefly, lipids were extracted from samples in the presence of internal standards (10 pmol of C_{17}-sphingosine and 30 pmol of C_{17}-S1P, Avanti Polar Lipids, Alabaster, AL). An aliquot of the lipid extract was transferred to a fresh tube with pre-added 40 pmol of N-palmitoyl-D-erythro-sphingosine (C17 base) (a kind gift of Dr Z. Szulc, Medical University of South Carolina) as an internal standard, and then subjected to alkaline hydrolysis to deacylate ceramide to sphingosine. The amount of S1P and SA1P was determined indirectly after dephosphorylation to sphingosine and sphinganine, respectively, with the use of alkaline phosphatase (bovine intestinal mucosa, Sigma). Free sphingosine and sphinganine, dephosphorylated sphingoid bases, and sphingo-sine released from ceramide were then converted to their o-phthalaldehyde derivatives and analyzed using a HPLC system (ProStar, Varian Inc., Palo Alto, CA) equipped with a fluorescence detector and C18 reversed-phase column (Varian Inc. OmniSpher 5, 4.6×150mm). The isocratic eluent composition of acetonitrile (Merck, Darmstadt, Germany): water (9:1, v/v) and a flow rate of 1 ml/min were used. Column temperature was maintained at 30°C [47].

**Statistical analysis**

Statistical calculations were performed using SAS 9.1 (USA). Data are presented as means +/- SD. P < 0.05 was considered significant in all analyses. Parameters between patients with HIV-lipodystrophy and healthy controls were compared with a Mann-Whitney test. Pearson’s correlations were used to examine the relationship between mRNA expression in muscle, sphingolipid in muscle and markers of insulin sensitivity, as well as with anthropometric parameters.

**Results**

**Baseline characteristics**

Demographic data, blood biochemistry and body composition appear in Table 1. The healthy men and the patients with HIV-lipodystrophy were age-matched. Two groups of healthy men were included due to lack of muscle tissue. Group 1 served as controls for the RT-PCR data. Group 2 served as controls for sphingolipid analysis.
Table 1. Baseline characteristics of patients and healthy controls.

| Variable                          | Healthy controls (n = 15) | Patients with HIV-LD (n = 23) | Healthy controls (n = 17) | Patients with HIV-LD (n = 14) |
|-----------------------------------|---------------------------|-------------------------------|---------------------------|-------------------------------|
| Age (years)                       | 47.5 (6.1)                | 47.9 (9.5)                    | 46.5 (6.0)                | 48.3 (9.7)                    |
| Duration of HIV infection (years) | 15.6 (9.6)                | 13.9 (7.0)                    |                           |                               |
| Duration of antiretroviral therapy (years) | 10.3 (4.3)                  | 8.9 (3.8)                      |                           |                               |
| CD4+ cell (cells/μl)              | 558 (208)                 | 550 (250)                     |                           |                               |
| LogHIV-RNA (copies/ml)            | 1.33 (0.12)               | 1.32 (0.11)                   |                           |                               |
| **Antiretroviral use**            |                           |                               |                           |                               |
| Current Tymidine-NRTI use, No. (%)| 11 (47.8)                 | 7 (50.0)                      |                           |                               |
| Current PI use, No. (%)           | 13 (56.7)                 | 8 (57.1)                      |                           |                               |
| Current NNRTI use, No. (%)        | 11 (47.8)                 | 7 (50.0)                      |                           |                               |
| **Physical activity parameters**  |                           |                               |                           |                               |
| VO_{2max} (LO_2/min)              | 2.5 (0.6)                 | 2.3 (0.5)                     | 3.4 (0.8)                 | 2.4 (0.5)                     |
| **Body composition**              |                           |                               |                           |                               |
| Body-mass index (kg/m^2)          | 23.7 (1.9)                | 23.7 (2.9)                    | 23.3 (2.1)                | 24.1 (3.0)                    |
| Weight (kg)                       | 76.9 (7.4)                | 73.6 (11.2)                   | 79.4 (9.0)                | 75.8 (11.1)                   |
| Waist (cm)                        | 90 (5.7)                  | 93.6 (6.4)                    | 91.1 (7.9)                | 94.2 (7.2)                    |
| Waist-to-hip ratio                | 0.94 (0.03)               | 1.01 (0.04)                   | 0.91 (0.05)               | 1.02 (0.04)                   |
| Fat mass (kg)                     | 15.7 (4.4)                | 13.8 (5.3)                    | 16.2 (6.4)                | 15.0 (5.3)                    |
| Trunk fat mass (kg)               | 8.9 (3.0)                 | 9.8 (3.9)                     | 9.1 (4.0)                 | 10.9 (4.0)                    |
| Trunk fat percentage (%)          | 56.1 (5.2)                | 71.2 (6.2)                    | 55.3 (5.1)                | 72.5 (5.8)                    |
| Limb fat mass (kg)                | 6.2 (1.5)                 | 3.5 (1.6)                     | 6.6 (2.5)                 | 3.6 (1.5)                     |
| Limb fat percentage (%)           | 40.2 (4.9)                | 25.1 (6.1)                    | 41.5 (4.2)                | 24.0 (5.7)                    |
| Trunk-to-limb fat ratio           | 1.4 (0.29)                | 3.09 (1.17)                   | 1.4 (0.25)                | 3.3 (1.3)                     |
| Lean mass (kg)                    | 58.2 (5.2)                | 57.0 (6.8)                    | 61.0 (5.4)                | 57.9 (6.2)                    |
| **Metabolic parameters**          |                           |                               |                           |                               |
| Total-cholesterol (mmol/L)        | 4.63 (0.64)               | 5.5 (0.9)                     | 4.81 (0.65)               | 5.8 (0.7)                     |
| HDL-C (mmol/L)                    | 1.51 (0.32)               | 1.23 (0.52)                   | 1.41 (0.32)               | 1.21 (0.36)                   |
| LDL-C (mmol/L)                    | 3.3 (0.6)                 | 3.7 (0.9)                     | 3.14 (0.74)               | 3.94 (0.81)                   |
| Triglycerides (mmol/L)            | 0.76 (0.24)               | 2.55 (1.43)                   | 0.96 (0.26)               | 2.88 (1.34)                   |
| Glucose (mmol/L)                  | 5.2 (0.3)                 | 5.4 (0.6)                     | 5.0 (0.1)                 | 5.4 (0.7)                     |
| Insulin (pmol/L)                  | 25 (8.9)                  | 52 (25)                       | 28.4 (9.9)                | 56.5 (28.2)                   |
| HOMA-IR                           | 0.99 (0.37)               | 2.2 (1.4)                     | 1.3 (0.14)                | 2.5 (1.5)                     |
| Glucose area under the curve (mmol/Lmin) | 670 (126)               | 826 (200)                     | 654 (153)                 | 779 (176)                     |
| Insulin area under the curve (pmol/Lmin) | 23505 (10598)            | 52360 (31017)                 | 18436 (10510)            | 45388 (37026)                 |

Two groups of healthy men were included due to lack of muscle tissue. Group 1 served as controls for the RT-PCR data. Group 2 served as controls for the sphingolipid analysis.

*Fourteen patients with HIV-LD are a part of the 23 patients with HIV-LD in group 1.

Data are presented as mean (SD). PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor. HOMA-IR, homeostatic model assessment for insulin resistance.

*P < 0.05;
**P < 0.01;
***P < 0.001,
****P < 0.0001 by t-test comparing patients with HIV-LD and healthy controls within each cohort.

https://doi.org/10.1371/journal.pone.0186755.t001
In group 1, patients were matched based on their VO$_2$ max. In group 2 we also tried to match HIV patients with their control based on physical activity, but at the end of the inclusion the HIV patients had lower levels of VO$_2$ max compared with controls (Table 1). Patients with HIV-lipodystrophy were characterised by reduced total limb fat mass, increased percentage of trunk fat mass, reduced percentage of limb fat mass and increased trunk-to-limb fat mass, indicating fat redistribution, compared to healthy controls. No differences were found regarding BMI, total fat mass, trunk fat mass or lean body mass.

Fasting triglycerides and total-cholesterol levels were higher in patients with HIV-lipodystrophy and so were fasting insulin, HOMA-IR and the insulin response during an OGTT when compared to control subjects from both group 1 and 2, indicating insulin resistance in patients with HIV-lipodystrophy (Table 1).

As previously demonstrated, plasma IL-18 was increased in patients with HIV-lipodystrophy compared to healthy controls (247 pg/ml (98) vs 199 pg/ml (102), p < 0.05).

**IL-18 and IL-18 receptor mRNA expression in skeletal muscle**

IL-18 mRNA (Fig 1A) and IL-18 receptor mRNA (Fig 1B) expression were reduced by 60% and 54%, respectively, in skeletal muscle in patients with HIV-lipodystrophy compared to healthy controls. (IL-18 mRNA: p = 0.0005 IL-18 receptor mRNA: p = 0.018). In the healthy control group, two subjects had very high levels of IL-18 mRNA. If these two subjects were excluded, IL-18 mRNA expression was still significantly lower in patients with HIV-lipodystrophy compared to healthy controls (p = 0.003) (data not shown).

**Sphingolipid in skeletal muscle**

The sphingolipids ceramide (Fig 2A) and sphingosine (Fig 2B) content in muscle tended to be elevated in patients with HIV-lipodystrophy compared to healthy controls (P = 0.06).
The sphinganine content in muscle tended to be lower in patients with HIV-lipodystrophy compared to healthy controls (Fig 2D, p = 0.06)

**Relationship between IL-18 mRNA and sphingolipid in skeletal muscle and circulating lipids**

In patients with HIV-lipodystrophy, low expression of IL-18 mRNA in skeletal muscle correlated to high levels of ceramides ($R_p = -0.56; p = 0.038$) (Fig 3A) and high levels of sphingosine-1P (IL-18 mRNA $R_p = -0.54, p = 0.046$) (Fig 3C). The same trend was observed for sphingosine ($R_p = -0.43, p = 0.12$) (Fig 3E). In healthy subjects, IL-18 mRNA in skeletal muscle did not correlate to muscle sphingolipids (Fig 3B, 3D and 3F), although the correlation for sphingosine-1P only included 8 samples and a possible correlation may be lost due to low n-value.

Reduced expression of IL-18 mRNA in skeletal muscle was associated with increased levels of circulating triglycerides in all subjects pooled together ($R_p = -0.73, p < 0.0001$) (Fig 3G). The same observation was found for IL-18R mRNA expression in skeletal muscle ($R_p = -0.56, p = 0.0004$, data not shown). When patients with HIV-lipodystrophy and healthy subjects were analysed individually, the same correlation between IL-18 mRNA and triglycerides...
Fig 3. The correlation relationship between muscle IL-18 mRNA and muscle sphingolipid content, circulating triglycerides and HDL-cholesterol in patients with HIV-lipodystrophy (to the right) and in healthy controls (to the left). IL-18 mRNA in muscle is negatively correlated to ceramide (A) and sphingosine-1P (C) content in muscle in patients with HIV-Lipodystrophy, but not in healthy controls (B, D, F). IL-18 mRNA in muscle is negatively correlated to triglycerides in patients with HIV-Lipodystrophy and in healthy controls (G), and positively correlated to...
remained (HIV-LD R_p = -0.51, p = 0.02; Healthy subjects R_p = -0.69, p = 0.014). Reduced expression of IL-18 mRNA and IL-18R mRNA in skeletal muscle was also associated with reduced levels of HDL-cholesterol in all subjects together (for IL-18 mRNA: R_p = 0.39, p = 0.01; for IL-18R mRNA: R_p = 0.48, p = 0.002) (Fig 3H) but not when the groups were analysed separately. No correlations were found between total-cholesterol or LDL-cholesterol and IL-18 mRNA (data not shown).

As patients with HIV-lipodystrophy had a lower VO\textsubscript{2} max than the healthy controls in group 2 we examined if the increased levels of sphingolipids were related to low levels of VO\textsubscript{2} max in patients with HIV-lipodystrophy. There was, however, no correlation between sphingolipids and VO\textsubscript{2}max/kg (ceramide R_p = 0.23, p = 0.42; Sphingosine-1P R_p = 0.20, p = 0.48; sphingosine R_p = 0.37, p = 0.19).

In addition, no correlation was found between muscle IL-18 mRNA expression and fat distribution (BMI, fat mass, limb or trunk fat mass) in healthy controls or in patients with HIV-lipodystrophy when analysed separately (data not shown).

No correlation was found between muscle IL-18 mRNA expression and glucose metabolism (plasma insulin, HOMA, glucose and insulin response during an OGGT) in healthy controls or in patients with HIV-lipodystrophy when analysed separately (data not shown).

**Expression of mitochondrial genes and fatty acid transporters in skeletal muscles and correlation to ceramide content in skeletal muscle**

Patients with HIV-lipodystrophy displayed lower mRNA expressions of β-hydroxy acyl-CoA dehydrogenase (β-HAD) (p = 0.004) (Fig 4A) and cytochrome c oxidase (p = 0.03) (Fig 4B) compared to controls. No differences between groups were observed for citrate synthase, CPT-1, and PGC-1 alpha (Fig 4C, 4D and 4E).

In patients with HIV-Lipodystrophy the content of ceramide in muscle correlated negative to the levels of β-HAD mRNA expressions (R = -0.61; p = 0.02) (Fig 4F), but not to cytochrome c oxidase (R = -0.10, p = 0.72) (Data not shown).

**Discussion**

The major finding of this study is that the expression of IL-18 mRNA and IL-18 receptor mRNA is reduced in skeletal muscle in patients with HIV-lipodystrophy compared to healthy age-matched men. Furthermore, low expression of muscle IL-18 mRNA correlates to high levels of ceramides in skeletal muscle and to increased levels of circulating triglycerides and low levels of HDL-cholesterol in patients with HIV-lipodystrophy.

**IL-18 and IL-18 receptor in skeletal muscle**

IL-18 is expressed in skeletal muscle [5] and high expression of IL-18 has been reported in skeletal muscle in inflammatory diseases such as inflammatory myopathies [48] and COPD [49]. Macrophages and dendritic cells are suggested to be the main producers of IL-18 [48]. Furthermore, it has been suggested that inflammation e.g. TNF-α trigger the IL-18 expression in skeletal muscle [50].

In contrast to those studies, we found a reduced expression of IL-18 and IL-18 Receptor mRNA in skeletal muscles in patients with HIV-lipodystrophy compared to healthy controls, although circulating IL-18 was increased in those patients. Therefore, we conclude that IL-18
Fig 4. Patients with HIV-Lipodystrophy have reduced levels of HAD mRNA (A) and Cytochrome c mRNA (B) in skeletal muscle, but no difference in citrate synthase mRNA (C), CPT-1 mRNA (D) and PGC-1 mRNA (E). HAD mRNA correlated negatively to the ceramide content (F). The levels of genes were calculated with GAPDH as a housekeeping gene. In the dot plots data for each subjects are given and the line represent means and SD. * P<0.05 and *** P<0.001 for healthy vs HIV-lipodystrophy patients. Regressions lines are given HIV-patients separately.

https://doi.org/10.1371/journal.pone.0186755.g004
signaling pathway is impaired in skeletal muscle in patients with HIV-lipodystrophy and that the muscle cell is not a source of circulating IL-18. Instead, we suggest that in healthy humans IL-18 is working in a local manner in skeletal muscle. It has previously been demonstrated that IL-18 mRNA is induced e.g. by TNF without influence circulating IL-18 [50]. Furthermore, several proteins (e.g. IL-8 and BDNF) are produced by skeletal muscle but not released into the circulation, and those proteins work via autocrine or paracrine mechanisms, exerting their effects on signalling pathways within the muscle itself [51].

The explanation for reduced IL-18 and IL-18 receptor expression in skeletal muscle is intriguing as the underlying mechanisms for the IL-18 production and IL-18 receptor regulation are still poorly understood. IL-18 production is tightly regulated, and achieved in a caspase-1 dependent or in a caspase-1-independent way. The components for cleavage of caspase-1, the inflammasome complexes, such as nucleotide-binding oligomerization domain receptors 1 (NLRP)-1, NLRP-3 and NLRC-4, is present in adipose tissue [52], and in skeletal muscle [53]. In adipose tissue, NLRP1 is an innate immune sensor that functions in the context of metabolic stress to produce IL-18, preventing obesity and diet-induced metabolic dysfunction [22,23]. NLRP1 is also highly expressed in skeletal muscle in humans [54], but it is unknown how NLRP1 is regulated in skeletal muscle and if NLRP-1 stimulates production of IL-18 in skeletal muscle, in a similar way as in adipose tissue.

The reduced IL-18 and IL-18 receptor in skeletal muscle in patients with HIV-Lipodystrophy may also be linked to IL-18 resistance. Obese subjects and persons with type 2 diabetes demonstrate impaired IL-18 responsiveness in leucocyte despite increased circulating levels of IL-18 [55]. The IL-18 receptor is suggested to be the responsible molecular site for the observed IL-18 resistance, as leucocyte from obese and type 2 diabetics demonstrated a reduced IL-18 receptor expression on leucocyte. However, no mechanism for reduced IL-18 receptor expression was found and the expression of IL-18 on the leucocyte was not measured. Netea and colleagues [55] explains IL-18 resistance as an immunological phenomenon; and hypothesize that a similar resistance to the metabolic effect of IL-18 is also present [55]. It is possible that the reduced IL-18 receptor expression in skeletal muscle found in the current study play a role in a resistance to the metabolic effects of IL-18. This has been shown for IL-6, where skeletal muscle in obesity-associated type 2 diabetes develops a resistance to IL-6 [56]. However, this hypothesis has to be tested in an in vitro study.

The role of IL-18 in lipid metabolism

In the last years, several animal studies have demonstrated that IL-18 play a role in metabolism, which is independent of its inflammatory role. Mice lacking IL-18 or the IL-18 receptor and therefore impaired IL-18 signalling become obese and display hyperinsulinemia, insulin resistance and dyslipidemia [19–21]. We found an inverse correlation between IL-18 expression in skeletal muscle and systemic triglycerides and HDL-cholesterol in both healthy subjects and in patients with HIV-lipodystrophy. Production of VLDL-TG is in part due to the increased flux of FFA to the liver in combination with insulin resistance associated hyperinsulinemia [57,58] and this may be a way linking the role of IL-18 in skeletal muscle to dyslipidemia.

In addition, IL-18 and IL-18 receptor deficient mice have an excess of intramyocellular lipids (IMCL) which in part is explained by impaired beta-oxidation in muscle due to a defect in one of major pathway that regulates fatty acid oxidation AMP-activated protein kinase (AMPK) [21]. Treating myotubes or skeletal muscle strips with IL-18 activates AMPK and increases fat oxidation. Furthermore, overexpression of IL-18 in mice leads to reduced fat mass, increased activation of AMPK and increased mRNA abundance of β-hydroxyacyl-CoA-
dehydrogenase (HAD), a key enzyme involved in mitochondrial function and hence increased fat oxidation [21], implicating IL-18 in metabolic homeostasis.

Having found that IL-18 mRNA expression was lower in skeletal muscle in patients with HIV-lipodystrophy, we investigated whether this was associated to an increased content of IMCL, as observed in mice lacking the IL-18 signalling pathway [21]. It is known that patients with HIV-lipodystrophy have increased level of IMCLs [24,30–32]. IMCLs are mainly composed by triacylglycerol but also include lipid intermediates such as diacylglycerol, sphingolipid, and phospholipid. Sphingolipids, including ceramide, sphingosine, sphingosine-1P and sphinganine have never been measured in skeletal muscle from patients with HIV-lipodystrophy, but are altered in other metabolic state such as obesity and type 2 diabetes. [59–61]. We found a trend towards increased contents of the sphingolipids ceramide and sphingosine, and that the reduced levels of IL-18 mRNA in muscle correlated with increased contents of ceramides and sphingosine-1P in patients with HIV-lipodystrophy, but not in healthy controls, demonstrating that skeletal muscle IL-18 and sphingolipids are linked. As this study is a cross-sectional study it is not possible to describe the causal relationship. Ceramide has been demonstrated to be involved in IL-18 production in macrophages and adipose tissue via increased production of reactive oxygen species, which acts as a secondary signal for NLRP3 activation leading to induction of caspase-1 cleavage and thereby increased IL-18 [62]. However, in the current study IL-18 expression was decreased and not increased in skeletal muscle in HIV-lipodystrophy, and ceramide can therefore not explain reduced expression of IL-18. In contrast, it is possible that low expression of IL-18 is causal involved in elevated content of ceramide, just like in the IL-18 deficient and IL-18 receptor deficient mice.

It is unknown whether increased level of ceramide is directly a cause of HAART, as no studies have demonstrated an effect of HAART per se on ceramide. Instead, hiv proteins (gp120 and TAT) can induces sphingolipids [63]. In our patients viral load was below the detection limits for all patients therefore it is unlikely that the increased levels of ceramide in muscle may be induced by hiv per se. Instead, ectopic lipid deposition is a part of the lipodystrophy syndrome seen in HAART treated HIV patients, and therefore the increased ceramide levels may be indirectly results of the antiretroviral therapy.

### IL-18 and mitochondrial activity

As described in rodents, IL-18 increases fatty acid oxidation through activation of AMPK and mitochondrial oxidation [21]. Patients with HIV-lipodystrophy display impaired fat oxidation [30] [29] and two recent studies show impaired mitochondrial oxidative phosphorylation [64,65] and activity of enzymes involved in fat oxidation; e.g. β-HAD and citrate synthase [33] in skeletal muscle in HIV patients. Our data is in accordance with those findings as we found reduced expression of β-HAD and cytochrome c oxidase mRNA in skeletal muscle in HIV patients with lipodystrophy. Furthermore, we showed that the ceramide content is negatively correlated with the expression of β-HAD. It has previously been demonstrated that ceramides alter mitochondrial dynamics in skeletal muscle [41] and therefore, impaired mitochondrial function may be secondary to increased ceramide observed in skeletal muscle in patients with HIV-LD. However, impaired mitochondrial fatty acid oxidation is also known to increase IMCLs, diacylglycerols, and ceramides [66].

As specific mRNA measurements correlated to each due to the use of the same housekeeping gene (GAPDH) it was not possible to make a correlational relationship analysis between IL-18 mRNA expression and mRNA expression of mitochondrial gene in our study. As a negative correlation between ceramide content and the expression of β-HAD mRNA as well as a negative correlation between ceramide content and the expression of IL-18 mRNA were
present, we can only speculate that IL-18 mRNA may correlate to expression of mitochondrial genes as well.

In conclusion, our findings suggest that muscular IL-18 may be involved in the regulation of intramuscular lipid metabolism and hypertriglyceridemia.

Acknowledgments
We thank the subjects for their participation in this study. Ruth Rousing, Hanne Willumsen, and Flemming Jessen are thanked for excellent technical help. The Danish HIV-Cohort is thanked for providing us HIV-related data.

Author Contributions
Conceptualization: Birgitte Lindegaard, Bente Klarlund Pedersen, Marcin Baranowski.

Data curation: Birgitte Lindegaard, Thine Hvid, Helene Wolsk Mygind, Ole Hartvig-Mortensen, Thomas Grøndal, Marcin Baranowski.

Formal analysis: Birgitte Lindegaard, Thine Hvid, Helene Wolsk Mygind, Ole Hartvig-Mortensen, Thomas Grøndal, Julie Abildgaard, Marcin Baranowski.

Funding acquisition: Birgitte Lindegaard, Bente Klarlund Pedersen.

Investigation: Birgitte Lindegaard, Thomas Grøndal.

Methodology: Birgitte Lindegaard, Thine Hvid, Ole Hartvig-Mortensen, Marcin Baranowski.

Project administration: Birgitte Lindegaard, Thine Hvid, Helene Wolsk Mygind, Thomas Grøndal.

Supervision: Ole Hartvig-Mortensen, Jan Gerstoft, Bente Klarlund Pedersen.

Validation: Birgitte Lindegaard, Marcin Baranowski.

Visualization: Birgitte Lindegaard.

Writing – original draft: Birgitte Lindegaard, Bente Klarlund Pedersen, Marcin Baranowski.

Writing – review & editing: Birgitte Lindegaard, Thine Hvid, Helene Wolsk Mygind, Ole Hartvig-Mortensen, Thomas Grøndal, Julie Abildgaard, Jan Gerstoft, Bente Klarlund Pedersen, Marcin Baranowski.

References
1. Okamura H, Tsutshi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88–91. https://doi.org/10.1038/378088a0 PMID: 7477296
2. Novick D, Kim S, Kaplanski G, Dinarello CA (2013) Interleukin-18, more than a Th1 cytokine. Semin Immunol 25: 439–448. https://doi.org/10.1016/j.smim.2013.10.014 PMID: 24275602
3. Fukami T, Miyazaki E, Matsumoto T, Kumamoto T, Tsuda T (2001) Elevated expression of interleukin-18 in the granulomatous lesions of muscular sarcoidosis. Clin Immunol 101: 12–20. https://doi.org/10.1006/clim.2001.5080 PMID: 11580222
4. Ploeggaard P, Penkova M, Pedersen BK (2005) Fiber type specific expression of TNF-alpha, IL-6 and IL-18 in human skeletal muscles. Exerc Immunol Rev 11:53–63. PMID: 16385844
5. Bruun JM, Stallknecht B, Helge JW, Richelsen B (2007) Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 157: 465–471. https://doi.org/10.1530/EJE-07-0206 PMID: 17893261
6. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A et al (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386: 619–623. https://doi.org/10.1038/386619a0 PMID: 9121567
IL-18 and IL-18 receptor expression and ceramides in muscles in HIV lipodystrophy

7. Alboni S, Cervia D, Sugama S, Conti B (2010) Interleukin 18 in the CNS. J Neuroinflammation 7:9. https://doi.org/10.1186/1742-2094-7-9 PMID: 20113500

8. Yoo JK, Kwon H, Khil LY, Zhang L, Jun HS, Yoon JW (2005) IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J Immunol 175: 8820–8826. PMID: 16339568

9. Chandrasekar B, Mummidi S, Valente AJ, Patel GN, Bailey SR, Freeman G et al (2005) The pro-inflammatory cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, and c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 280: 26263–26277. https://doi.org/10.1074/jbc.M502586200 PMID: 15890643

10. Kalina U, Kauschat D, Koyama N, Nuernberger H, Ballas K, Koschmieder S et al (2000) IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-2. J Immunol 165: 1307–1313. PMID: 10903731

11. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y et al (1999) Cutting edge: generation of IL-1 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 162: 5041–5044. PMID: 10227969

12. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G et al (2002) Weight loss reduces interleukin-18 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, and c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 280: 26263–26277. https://doi.org/10.1074/jbc.M502586200 PMID: 15890643

13. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S et al (2003) Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationships with diabetic nephropathy. Metabolism 52: 605–608. https://doi.org/10.1053/meta.2003.50096 PMID: 12759891

14. Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T (2003) Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 26: 2622–2627. PMID: 12941729

15. Wood IS, Wang B, Jenkins JR, Trayhurn P (2005) The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNF-alpha in human adipocytes. Biochem Biophys Res Commun 337: 422–429. https://doi.org/10.1016/j.bbrc.2005.09.068 PMID: 16188228

16. Fain JN, Tichansky DS, Madan AK (2006) Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism 55: 1113–1121. https://doi.org/10.1016/j.metabol.2006.04.008 PMID: 16839849

17. Koenen TB, Stienstra R, van Tits LJ, Joosten LA, van Velzen JF, Hijmans A et al (2011) The inflammatory cytokine interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationships with diabetic nephropathy. Metabolism 52: 605–608. https://doi.org/10.1053/meta.2003.50096 PMID: 12759891

18. Spoto B, Di BE, Mattace-Raso F, Sijbrands E, Vliardi A, Parlongo RM, Pizzini P et al (2014) Pro-inflammatory cytokine IL-18 expression in subcutaneous and visceral fat in severe obesity. Nutr Metab Cardiovasc Dis 24: 1137–1143. https://doi.org/10.1016/j.numecd.2014.04.017 PMID: 24984824

19. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ et al (2006) Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 12: 650–656. https://doi.org/10.1038/nm1415 PMID: 16732281

20. Zorrilla EP, Sanchez-Alavez M, Sugama S, Brennan M, Fernandez R, Bartfai T et al (2007) Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci USA 104: 11097–11102. https://doi.org/10.1073/pnas.0611523104 PMID: 17578927

21. Lindegaard B, Matthews VB, Brandt C, Hojman P, Allen TL, Espevæ F et al (2013) Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice. Diabetes 62: 3064–3074. https://doi.org/10.2337/db12-1095 PMID: 23670974

22. Lee MK, Yvan-Charet L, Masters SL, Murphy AJ (2016) The modern interleukin-1 superfamily: Divergent roles in obesity. Semin Immunol 28: 441–449. https://doi.org/10.1016/j.smim.2016.10.001 PMID: 27726910

23. Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, Lee MK, Lawlor KE et al (2016) IL-18 Production from the NLRP1 Inflammasome Prevents Obesity and Metabolic Syndrome. Cell Metab 23: 155–164. https://doi.org/10.1016/j.cmet.2015.09.024 PMID: 26603191

24. Villarroya F, Domingo P, Giralt M (2010) Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta 1801: 392–399. https://doi.org/10.1016/j.bbalip.2009.09.018 PMID: 19800025
25. Capeau J (2007) From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging. Curr Opin HIV AIDS 2: 247–252. https://doi.org/10.1097/COH.0b013e3281e66919 PMID: 19372895

26. de WR, Cohen K, Maartens G (2013) Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 8: e63623. https://doi.org/10.1371/journal.pone.0063623 PMID: 23723990

27. Sievers M, Walker UA, Sevastianova K, Setzer B, Wagstaff D, Eriksson P et al (2009) Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis 200: 252–262. https://doi.org/10.1086/599986 PMID: 19519254

28. Villarroya F, Domingo P, Giralt M (2007) Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies. Curr Opin HIV AIDS 2: 261–267. https://doi.org/10.1097/COH.0b013e32810d785 PMID: 19372897

29. Vassimon HS, de Paula FJ, Machado AA, Monteiro JP, Jordao AA Jr. (2012) Hypermetabolism and altered substrate oxidation in HIV-infected patients with lipodystrophy. Nutrition 28: 912–916. https://doi.org/10.1016/j.nut.2011.12.010 PMID: 22503533

30. Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliato E et al (2003) Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 284: E274–E280. https://doi.org/10.1152/ajpendo.00391.2001 PMID: 12388139

31. Torriani M, Hadigan C, Jensen ME, Grinspoon S (2003) Psoas muscle attenuation measurement with computed tomography indicates intra-muscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol (1985) 95(3):1005–10

32. Gallego-Escuredo JM, Villarroya J, Domingo P, Targarona EM, Alegre M, Domingo JC et al (2013) Differential altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy. J Acquir Immune Defic Syndr 64: 142–148. https://doi.org/10.1097/QAI.0b013e318289bb67 PMID: 23714743

33. Amati F, Dube JJ, Alvarez-Camero E, Edreira MM, Chometnowski P, Coen PM et al (2011) Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes? Diabetes 60: 2588–2597. https://doi.org/10.2337/db10-1221 PMID: 21873552

34. Kitessa SM, Ayebywardena MY (2016) Lipid-Induced Insulin Resistance in Skeletal Muscle: The Chase for the Culprit Goes from Total Intramuscular Fat to Lipid Intermediates, and Finally to Species of Lipid Intermediates. Nutrients 8.

35. Bergman BC, Brozinick JT, Strauss A, Bacon S, Keree A, Bui HH et al (2016) Muscle sphingolipids during rest and exercise: a C18:0 signature for insulin resistance in humans. Diabetologia 59: 785–798. https://doi.org/10.1007/s00125-015-3850-y PMID: 26739615

36. Park M, Kaddai V, Ching J, Fridianoto KT, Sieli RJ, Sugii S et al (2016) A Role for Ceramides, but Not Sphingomyelins, as Antagonists of Insulin Signaling and Mitochondrial Metabolism in C2C12 Myotubes. J Biol Chem 291: 23978–23988. https://doi.org/10.1074/jbc.M116.737684 PMID: 27703011

37. Lindegaard B, Hansen AB, Pedersen BK (2004) High plasma level of interleukin-18 in HIV-infected subjects with lipodystrophy. J Acquir Immune Defic Syndr 36: 588–593. PMID: 15097301

38. Falasca K, Ucciferri C, Manzoli L, Mancino P, Pizzigallo E, Conti P et al (2007) Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol 20: 519–527. https://doi.org/10.1177/039463200702000310 PMID: 17880765

39. Ortmeyer HK, Ryan AS, Hafer-Macko C, Oursler KK (2016) Skeletal muscle cellular metabolism in older HIV-infected men. Physiol Rep 4.

40. Lindegaard B, Hansen AB, Pederson BK (2004) Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 284: E274–E280. https://doi.org/10.1152/ajpendo.00391.2001 PMID: 12388139

41. Sievers M, Walker UA, Sevastianova K, Setzer B, Wagstaff D, Eriksson P et al (2009) Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis 200: 252–262. https://doi.org/10.1086/599986 PMID: 19519254

42. Villarroya F, Domingo P, Giralt M (2007) Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies. Curr Opin HIV AIDS 2: 261–267. https://doi.org/10.1097/COH.0b013e32810d785 PMID: 19372897

43. Gallego-Escuredo JM, Villarroya J, Domingo P, Targarona EM, Alegre M, Domingo JC et al (2013) Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy. J Acquir Immune Defic Syndr 64: 142–148. https://doi.org/10.1097/QAI.0b013e318289bb67 PMID: 23714743

44. Lindegaard B, Hansen AB, Pedersen BK (2004) Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 284: E274–E280. https://doi.org/10.1152/ajpendo.00391.2001 PMID: 12388139

45. Kitessa SM, Ayebywardena MY (2016) Lipid-Induced Insulin Resistance in Skeletal Muscle: The Chase for the Culprit Goes from Total Intramuscular Fat to Lipid Intermediates, and Finally to Species of Lipid Intermediates. Nutrients 8.

46. Bergman BC, Brozinick JT, Strauss A, Bacon S, Keree A, Bui HH et al (2016) Muscle sphingolipids during rest and exercise: a C18:0 signature for insulin resistance in humans. Diabetologia 59: 785–798. https://doi.org/10.1007/s00125-015-3850-y PMID: 26739615

47. Park M, Kaddai V, Ching J, Fridianoto KT, Sieli RJ, Sugii S et al (2016) A Role for Ceramides, but Not Sphingomyelins, as Antagonists of Insulin Signaling and Mitochondrial Metabolism in C2C12 Myotubes. J Biol Chem 291: 23978–23988. https://doi.org/10.1074/jbc.M116.737684 PMID: 27703011

48. Lindegaard B, Hvid T, Grondahl T, Froisig C, Gerstoft J, Hofman P et al (2013) Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV. PLoS One 8: e55632. https://doi.org/10.1371/journal.pone.0055632 PMID: 23733568

49. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361: 726–735. PMID: 12620736

50. Lindegaard B, Hansen T, Hvid T, van HG, Plomgaard P, Ditlevsen S et al (2008) The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-
infected patients with lipodystrophy. J Clin Endocrinol Metab 93: 3860–3869. https://doi.org/10.1210/jc.2007-2733 PMID: 18628529

45. Buchfuhrer MJ, Hansen JE, Robinson TE, Sue DY, Wasserman K, Whipp BJ (1983) Optimizing the exercise protocol for cardiopulmonary assessment. J Appl Physiol 55: 1558–1564. https://doi.org/10.1152/jappl.1983.55.5.1558 PMID: 6643191

46. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419. PMID: 3899825

47. Knapp M, Lisowska A, Zabielski P, Musial W, Baranowski M (2013) Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. Prostaglandins Other Lipid Mediat 106: 53–61. https://doi.org/10.1016/j.prostaglandins.2013.10.001 PMID: 24120760

48. Tucci M, Quatraro C, Dammacco F, Silvestris F (2006) Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 146: 21–31. https://doi.org/10.1111/j.1365-2249.2006.03180.x PMID: 16968394

49. Petersen AM, Penkowa M, Iversen M, Frydelund-Larsen L, Andersen JL, Mortensen J et al (2007) Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung 185: 161–171. https://doi.org/10.1007/s00408-007-9000-7 PMID: 17436040

50. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK (2006) Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 291: E108–E114. https://doi.org/10.1152/ajpendo.00471.2005 PMID: 16464907

51. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8: 457–465. https://doi.org/10.1038/nrendo.2012.49 PMID: 22473333

52. Smart MC, Dedousis G, Yannakouris N, Grisoni ML, Dror GK, Yannakoulia M et al (2011) Genetic variation within IL18 is associated with insulin levels, insulin resistance and postprandial measures. Nutr Metab Cardiovasc Dis 21: 476–484. https://doi.org/10.1016/j.numecd.2009.12.004 PMID: 20227263

53. Benetti E, Chiazza F, Patel NS, Collino M (2013) The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediators Inflamm 2013: 678627. https://doi.org/10.1155/2013/678627 PMID: 23843683

54. Lech M, Avila-Ferrufino A, Skuginna V, Susanti HE, Anders HJ (2010) Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol 22: 717–728. https://doi.org/10.1093/intimm/dxq058 PMID: 20584763

55. Zilverschuur GR, Tack CJ, Joosten LA, Kullberg BJ, Van Der Meer JW, Netea MG (2008) Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. Int J Obes (Lond).

56. Scheele C, Nielsen S, Kelly M, Broholm C, Nielsen AR, Taudorf S et al (2012) Satellite cells derived from obese humans with type 2 diabetes and differentiated into myocytes in vitro exhibit abnormal response to IL-6. PLoS One 7: e39657. https://doi.org/10.1371/journal.pone.0039657 PMID: 22761857

57. Adams JM, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC et al (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53: 24–31. PMID: 14693694

58. Straczkowski M, Kowalska I, Baranowski M, Nikolajuk A, Otziomek E, Zabielski P et al (2007) Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes. Diabetologia 50: 2366–2373. https://doi.org/10.1007/s00125-007-0781-2 PMID: 17724577

59. Cohn PM, Dubé JJ, Amati F, Stefanovic-Racic M, Ferrell RE, Toledo FG et al (2010) Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 59: 80–88. https://doi.org/10.2337/db09-0988 PMID: 19838981

60. Sharma D, Kanneganti TD (2016) The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation. J Cell Biol 213: 617–629. https://doi.org/10.1083/jcb.201602089 PMID: 27325789

61. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA et al (2004) Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55: 257–267. https://doi.org/10.1002/ana.10828 PMID: 14755730
64. Payne BA, Wilson IJ, Hateley CA, Horvath R, Santibanez-Koref M, Samuels DC et al (2011) Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 43: 806–810. https://doi.org/10.1038/ng.863 PMID: 21706004

65. Maagaard A, Holberg-Petersen M, Kollberg G, Oldfors A, Sandvik L, Bruun JN (2006) Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 11: 601–608. PMID: 16964828

66. Wicks SE, Vandanmagsar B, Haynie KR, Fuller SE, Warfel JD, Stephens JM et al (2015) Impaired mitochondrial fat oxidation induces adaptive remodeling of muscle metabolism. Proc Natl Acad Sci U S A 112: E3300–E3309. https://doi.org/10.1073/pnas.1418560112 PMID: 26056297